Table 5. . Summary of literature review reporting treatment outcome of immune checkpoint inhibitor in mucosal melanoma.
| Study | Agent | n | ORR (%) | CR (%) | DCR (%) | mPFS (month) | mOS (month) | Ref. |
|---|---|---|---|---|---|---|---|---|
| Postow et al. | Ipilimumab | 30 | 6.7 | 0.3 (n = 1) | 26.7 | N/A | 6.4 | [16] |
| Alexander et al. | Ipilimumab | 8 | N/A | N/A | N/A | 2.7 | 5.8 | [17] |
| Del vecchio et al. | Ipilimumab | 71 | 11.3 | 0.01 (n = 1) | 35.2 | 4.3 | 6.4 | [18] |
| Zimmer et al. | Ipilimumab | 6 | 17 | 0 | 50 | N/A | 9.6 | [19] |
| Shoushtari et al. | Anti-PD1† | 35 | 22.9 | 0 | 42.9 | 3.9 | 12.4 | [15] |
| D'angelo et al. | Nivolumab | 86 | 23.3 | 5.8 (n = 5) | 45.3 | 3.0 | N/A | [14] |
| Ipilimumab | 36 | 8.3 | 0 | 16.7 | 2.7 | N/A | ||
| Ipilimumab + nivolumab | 35 | 37.1 | 2.9 (n = 1) | 57.1 | 5.9 | N/A | ||
| Takahashi et al. | Nivolumab | 27 | 33.3 | 7.4 (n = 2) | 40.7 | N/A | N/A | [20] |
| Butler et al. | Pembrolizumab | 84 | 19 | N/A | 31 | 2.8 | 11.3 | [13] |
| Schaefer et al. | Ipilimumab | 8 | 12.5 | 0 | 25 | N/A | N/A | [21] |
| Anti-PD1† | 7 | 28.6 | 0 | 28.6 | N/A | N/A | ||
†Either nivolumab or pembrolizumab.
CR: Complete response; DCR: Disease control rate; mOS: Median overall survival; mPFS: Median progression-free survival; n: Number; N/A: Not available; ORR: Objective response rate.